Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy(POLO) | completed | Phase 3 | 154 | AstraZenecaINDUSTRY | 12 | Sep 13, 2023 | clinicaltrials |
| NCT01830621 | BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma | completed | Phase 3 | 282 | NCIC Clinical Trials GroupNETWORK | 3 | Aug 28, 2023 |
| clinicaltrials |
| NCT00079066 | Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer | completed | Phase 3 | 572 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 4, 2023 | clinicaltrials |
| NCT00640471 | Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer | completed | Phase 3 | 750 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT00057876 | Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer | completed | Phase 3 | 74 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jul 5, 2023 | clinicaltrials |
| NCT00979680 | Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma(GRECCAR1) | completed | Phase 3 | 207 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00003057 | Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer | completed | Phase 3 | 500 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02973685 | HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. | completed | Phase 3 | 315 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03126435 | EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX | completed | Phase 3 | 218 | SynCore Biotechnology Co., Ltd.INDUSTRY | 7 | May 6, 2023 | clinicaltrials |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy(EPIC-1511) | completed | Phase 3 | 480 | Centre Oscar LambretOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT02494583 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | completed | Phase 3 | 763 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 13, 2023 | clinicaltrials |
| NCT00202774 | Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer | completed | Phase 3 | 348 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01718873 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer(OBELICS) | completed | Phase 3 | 230 | National Cancer Institute, NaplesOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02564263 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | completed | Phase 3 | 628 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 13, 2023 | clinicaltrials |
| NCT03745170 | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | completed | Phase 3 | 650 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 1, 2023 | clinicaltrials |
| NCT02438436 | Simo Decoction and Gum Chewing for Bowel Activity(SD/GC-HCC) | completed | Phase 3 | 180 | Guangxi Medical UniversityOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein(REACH-2) | completed | Phase 3 | 399 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 20, 2023 | clinicaltrials |
| NCT02948309 | Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer(MISTRAL) | completed | Phase 3 | 290 | Karolinska University HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03231722 | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS(TRIPLETE) | completed | Phase 3 | 435 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT00642577 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer. | completed | Phase 3 | 214 | Hoffmann-La RocheINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT03691090 | Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer | completed | Phase 3 | 596 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT02870582 | Donafenib for Previously Treated Metastatic Colorectal Cancer | completed | Phase 3 | 536 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT00113763 | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 463 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT00364013 | PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy | completed | Phase 3 | 1,183 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT01099449 | Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy | completed | Phase 3 | 362 | Alliance for Clinical Trials in OncologyOTHER | 2 | Nov 3, 2022 | clinicaltrials |
| NCT01926197 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | completed | Phase 3 | 27 | Stanford UniversityOTHER | 2 | Oct 28, 2022 | clinicaltrials |
| NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC(Trybeca-1) | completed | Phase 3 | 512 | ERYtech PharmaINDUSTRY | 3 | Oct 18, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT00339183 | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone | completed | Phase 3 | 1,186 | AmgenINDUSTRY | 0 | Sep 23, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT01648894 | Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer(GRECCAR6) | completed | Phase 3 | 265 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02661971 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)(RAMSES/FLOT7) | completed | Phase 2 / Phase 3 | 180 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT03042611 | A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer(ANGEL) | completed | Phase 3 | 460 | Elevar TherapeuticsINDUSTRY | 12 | Jul 8, 2022 | clinicaltrials |
| NCT02569242 | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer | completed | Phase 3 | 419 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 8 | Jul 6, 2022 | clinicaltrials |
| NCT00655876 | Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | completed | Phase 3 | 344 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 14, 2022 | clinicaltrials |
| NCT02898077 | A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | completed | Phase 3 | 440 | Eli Lilly and CompanyINDUSTRY | 4 | Jun 14, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT00389870 | Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil | completed | Phase 3 | 1,198 | University of LeedsOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT01137123 | Improve the Treatment of Thoracic Esophageal Cancer | completed | Phase 3 | 301 | Sun Yat-sen UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01164202 | Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer(SATURNE) | completed | Phase 2 / Phase 3 | 78 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT02591030 | Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours(AMEBICA) | completed | Phase 2 / Phase 3 | 191 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01962246 | Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction(A-C) | completed | Phase 2 / Phase 3 | 169 | Hebei Medical UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT02459457 | A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer | completed | Phase 3 | 321 | Fudan UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT02322593 | Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer(SOLAR) | completed | Phase 3 | 711 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 2 | Dec 20, 2021 | clinicaltrials |
| NCT00995202 | Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer(SURVEILLANCE) | completed | Phase 3 | 1,997 | Federation Francophone de Cancerologie DigestiveOTHER | 3 | Dec 7, 2021 | clinicaltrials |
| NCT01308190 | Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer | completed | Phase 3 | 173 | Corporacion Parc TauliOTHER | 1 | Nov 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2023source: clinicaltrials